Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. At42617
2. 2296814-85-0
| Molecular Weight | 4167 g/mol |
|---|---|
| Molecular Formula | C192H302N46O57 |
| XLogP3 | -5 |
| Hydrogen Bond Donor Count | 57 |
| Hydrogen Bond Acceptor Count | 62 |
| Rotatable Bond Count | 148 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 1660 |
| Heavy Atom Count | 295 |
| Formal Charge | 0 |
| Complexity | 9920 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 40 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Dapiglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Profil Institut für Stoffwechselforschung GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2025
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dapiglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 06, 2025
Details:
ZP7570 (dapiglutide), a long-acting GLP-1/GLP-2 receptor dual agonist, it is being developed for weight management in obese patients.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2024
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Reports Positive Results from Phase 1b Trial of Dapiglutide
Details : ZP7570 (dapiglutide), a long-acting GLP-1/GLP-2 receptor dual agonist, it is being developed for weight management in obese patients.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 09, 2024
Details:
The net proceeds from the Offering are intended to advance ZP7570 (dapiglutide), a GLP-1/GLP-2 receptor dual agonist in phase 2 trials for obesity patients.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Goldman Sachs International
Deal Size: $900.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 25, 2024
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Goldman Sachs International
Deal Size : $900.0 million
Deal Type : Public Offering
Zealand Pharma Launches Equity Offering Raising USD 900 Million / DKK 6.257 Billion
Details : The net proceeds from the Offering are intended to advance ZP7570 (dapiglutide), a GLP-1/GLP-2 receptor dual agonist in phase 2 trials for obesity patients.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
June 25, 2024
Details:
The net proceeds from the Offering are intended to advance ZP7570 (dapiglutide), a GLP-1/GLP-2 receptor dual agonist in phase 2 trials for obesity patients.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Goldman Sachs International
Deal Size: $1,000.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 25, 2024
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Goldman Sachs International
Deal Size : $1,000.0 million
Deal Type : Public Offering
Zealand Pharma Completes Upsized Equity Offering Raising $1 Billion in Gross Proceeds
Details : The net proceeds from the Offering are intended to advance ZP7570 (dapiglutide), a GLP-1/GLP-2 receptor dual agonist in phase 2 trials for obesity patients.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
June 25, 2024
Details:
ZP7570 (dapiglutide) is a first-in-class peptide, long-acting, dual GLP-1 /GLP-2 receptor agonist and is being developed for the potential treatment of obesity.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2024
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Shares Results from DREAM Trial of Dapiglutide in Obesity
Details : ZP7570 (dapiglutide) is a first-in-class peptide, long-acting, dual GLP-1 /GLP-2 receptor agonist and is being developed for the potential treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 23, 2024
Details:
Dapiglutide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Zealand Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2023
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Dapiglutide for the Treatment of Obesity
Details : Dapiglutide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 29, 2023
Details:
Dapiglutide (pINN) is a long-acting GLP-1R/GLP-2R dual agonist. Results showed a plasma half-life allowing for once weekly dosing and effects on several biomarkers suggest clinically relevant exposures of ZP7570 were achieved.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2022
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dapiglutide (pINN) is a long-acting GLP-1R/GLP-2R dual agonist. Results showed a plasma half-life allowing for once weekly dosing and effects on several biomarkers suggest clinically relevant exposures of ZP7570 were achieved.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 06, 2022
Details:
ZP7570 (dapiglutide), a novel GLP1/GLP2 dual agonist and preclinical data on the antidiabetic potential of the company’s long-acting amylin analogue ZP8396.
Lead Product(s): Dapiglutide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Boehringer Ingelheim GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2022
Lead Product(s) : Dapiglutide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZP7570 (dapiglutide), a novel GLP1/GLP2 dual agonist and preclinical data on the antidiabetic potential of the company’s long-acting amylin analogue ZP8396.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
64
PharmaCompass offers a list of Dapiglutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dapiglutide manufacturer or Dapiglutide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dapiglutide manufacturer or Dapiglutide supplier.
PharmaCompass also assists you with knowing the Dapiglutide API Price utilized in the formulation of products. Dapiglutide API Price is not always fixed or binding as the Dapiglutide Price is obtained through a variety of data sources. The Dapiglutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dapiglutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dapiglutide, including repackagers and relabelers. The FDA regulates Dapiglutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dapiglutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dapiglutide supplier is an individual or a company that provides Dapiglutide active pharmaceutical ingredient (API) or Dapiglutide finished formulations upon request. The Dapiglutide suppliers may include Dapiglutide API manufacturers, exporters, distributors and traders.
Dapiglutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dapiglutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dapiglutide GMP manufacturer or Dapiglutide GMP API supplier for your needs.
A Dapiglutide CoA (Certificate of Analysis) is a formal document that attests to Dapiglutide's compliance with Dapiglutide specifications and serves as a tool for batch-level quality control.
Dapiglutide CoA mostly includes findings from lab analyses of a specific batch. For each Dapiglutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dapiglutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Dapiglutide EP), Dapiglutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dapiglutide USP).
